Koios Medical, Inc. articles

• After implementation of AI decision support, the benign biopsy rate decreased from 71.79% to 59.2% while the overall biopsy rate stayed constant.
• PPV3 increased from 28.2% to 40.8%.

Objective
To examine the affect of prospective AI decision support (Koios DS Breast) use on breast ultrasound biopsy performance metrics.

Materials and Methods
Non-identifiable HIPAA compliant data collected for QI/QA purposes